LCTX (Lineage Cell Therapeutics) Expected net earnings per share growth this year

Patent protection and lobbying resources guarantee the stability of Lineage Cell Therapeutics (LCTX). Comparing the annual EPS growth trajectory on GURU.Markets confirms this reliability, where the value 79.40 shows the current figure. Leadership in vision regeneration provides the company with pricing power, while a steady influx of grants eliminates liquidity shortages during clinical trials.

LCTX - Lineage Cell Therapeutics Earnings growth in current year over the range 07/04/2022 - 11/13/2026

Financial and market metric breakdowns for Lineage Cell Therapeutics (LCTX)

- share price and consensus valuation forecast:

Price Chart Lineage Cell Therapeutics Inc|LCTX - Analyst Consensus Forecast

- business market valuation indicators:

Market Capitalization Lineage Corp|LCTX - Total Company Value

- shareholders' equity book value data:

Equity per Share Lineage Cell Therapeutics|LCTX - Book Capitalization|Market-to-Book Ratio lineagecell.com|LCTX - Company Total Assets

- debt and liquidity details:

Total Debt to Capital Lineage Cell Therapeutics|LCTX - Long-Term Debt to Capital|Short-Term Indebtedness to Equity lineagecell.com|LCTX - Company Aggregate Debts|Debts to Book Value Lineage Corp|LCTX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Lineage Cell Therapeutics|Quick Liquidity Indicator lineagecell.com

- earnings and market ratios statistics:

LCTX - Net Profit|Expected Net Profit Lineage Cell Therapeutics|LCTX - Price to Earnings Ratio|Future Price to Earnings Lineage Corp|LCTX - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lineage Corp|LCTX - Operating profit before deduction of amortization|Earnings per share for the trailing year Lineage Cell Therapeutics|LCTX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months lineagecell.com|LCTX - Earnings growth in current year|Expected earnings per share trend next year Lineage Cell Therapeutics

Fundamental valuation:LCTX Lineage Cell Therapeutics Inc

Manufactured product of Lineage Cell Therapeutics

This indicator measures the annual growth rate of earnings per share, allowing for an assessment of business capitalization efficiency by comparing current and prior periods. The analysis of annual earnings per share percentage dynamics on GURU.Markets confirms how investments in the modernization of Lineage Cell Therapeutics (LCTX) clean rooms and the scaling of cell lines are converting into tangible financial results.

Key competitors

MESO (Mesoblast Ltd) - Earnings per share growth in current year|SRZN (Surrozen Corp) - Earnings growth in current year|Cryo-Cell International Inc (CCEL) - Expected net earnings per share growth this year|Earnings per share growth in current year FibroBiologics, Inc. (FBLG)|longeveron.com - Earnings per share growth this year|Earnings growth in current year BRTX (BioRestorative Therapies, Inc.)|Creative Medical Technology Holdings, Inc. (CELZ) - Earnings per share growth rate in current year